liraglutide vs semaglutide diabetes vs. liraglutide: Head-to-head study reveals a risk difference GLP-1 DRUGS: THE FUTURE OF

It is estimated that the glucagon-like peptide-1 (GLP-1) market will exceed US$100 billion (80.3 billion) by 2030, driven equally by diabetes and obesity usage

doi:10.17226/10997

Loss of muscle mass When people lose weight through dieting, medication, or bariatric surgery, about one-third of the weight lost is lean mass, Almandoz explained

This percentage will vary quite a bit, case by case, depending on a number of factors, one of the most important of which includes how the patient responds to the medication and if they are able to continue increasing the dosage of the medication so that it becomes more effective